Table 1. Characteristics of studies assessing the expression of MAD2 immunohistochemistry in cancer.
| Author | Year | Cancer site(s) | Samples assessed | Age range, years (mean or median) | Sex | Number of normal tissue samples | Number of cancer samples | Site of staining | Expression analysis | Survival analysis |
|---|---|---|---|---|---|---|---|---|---|---|
| Agosten | 2007 | Breast | TMA | NR | Females | NR | 85 | Perinuclear/cytoplasmic | ✓ | X |
| Burum-Auensen | 2008 | Colorectal | TMA | 35–88 (68) | Males & females | 17 | 55 | Nuclear | ✓ | ✓ |
| Burum-Auensen | 2007 | Colorectal (UC-related) |
TMA | NR | NR | 10 | 8 | Nuclear/additional staining was cytoplasmic | ✓ | X |
| Burum-Auensen | 2010 | Testicular | TMA | NR | Males | 21 | 336 | Nuclear with weak staining of cytoplasm | ✓ | X |
| Choi | 2013 | Bladder | TMA | 23–97 (68) | Males & females | NR | 339 | Nuclear & cytoplasmic | ✓ | ✓ |
| Du | 2011 | Breast | NR | 33–83 (54) | Females | NR | 117 | Nuclear/sometimes cytoplasmic | ✓ | X |
| Fung | 2007 | Testicular | NR | 24–67 (37.7) | Males | 12 | 23 | Nuclear & cytoplasmic | ✓ | X |
| Furlong | 2012 | Ovarian | TMA and full face | NR | Females | NR | 82 | Nuclear | ✓ | ✓ |
| Genga | 2015 | Myelodysplastic syndrome | NR | 18–91 (59.5) | Males & females | 10 | 40 | Cytoplasmic | ✓ | ✓ |
| Gladhaug | 2010 | Pancreatic | TMA | NR | Males & females | NR | 218 | Nuclear | ✓ | ✓ |
| Hannisdal | 2010 | Tonsillar | TMA | 43 aged < 60 57 aged ≥ 60 |
Males & females | NR | 105 | Nuclear & cytoplasmic | ✓ | ✓ |
| Hisaoka | 2008 | Sarcoma | NR | NR | NR | 50 | 50 | Nuclear | ✓ | X |
| Kato | 2012 | Lung | TMA | 123 aged < 60 239 aged ≥ 60 |
Males & females | NR | 362 | NR | ✓ | X |
| Kato | 2011 | Lung | TMA | 26–87 (63.5) | Males & females | NR | 358 | Nucleoplasmic | ✓ | ✓ |
| Kim | 2014 | Uterine cervical | TMA | 22–82 (44.1) | Females | 100 | 232 | Nuclear & cytoplasmic | ✓ | ✓ |
| Ko | 2010 | Salivary duct | NR | 42–82 (58.5) | Males & females | NR | 27 | Cytoplasmic | ✓ | ✓ |
| Li | 2013 | Endometrial | NR | 35–85 (51) | Females | 30 normal, 30 hyperplasia | 63 | Nuclear & cytoplasmic | ✓ | ✓ |
| Li | 2003 | Colorectal | NR | 28–81 (54.8) | Males & females | 38 | 38 | Brown-yellow staining mainly in cell plasma | ✓ | X |
| Li | 2004 | Colorectal | NR | 25–79 (52.5) | Males & females | 40 | 40 | Brown-yellow staining mainly in cell plasma | ✓ | ✓ |
| Liao | 2013 | Cervical | NR | 23–65 (43.5) | Females | 10 | 90 | Nuclear & cytoplasmic | ✓ | X |
| McGrogan | 2014 | Ovarian | TMA | 32–77 (52) | Females | NA | 72 | Nuclear | ✓ | ✓ |
| Morishta | 2012 | Uterine cervical | NR | 22–69 | Females | NA | 53 | Nuclear | ✓ | X |
| Nakano | 2012 | Ovarian serous | NR | 26–82 | Females | NA | 41 | Nuclear | ✓ | ✓ |
| Nakano | 2012 | Ovarian mucinous | NR | 13–88 | Females | 30 | 98 | Nuclear | ✓ | ✓ |
| Park | 2013 | Ovarian | NR | 59 aged < 60 26 aged ≥ 60 |
Females | NA | 85 | Nuclear 7 cytoplasmic | ✓ | ✓ |
| Rizzardi | 2014 | Oral SCC | NR | 44–86 (61) | Males & females | NA | 49 | Nuclear | ✓ | ✓ |
| Sotillo | 2006 | Various | TMA | NR | NR | NA | 351 | Nuclear | ✓ | X |
| Suraokar | 2014 | Mesothelioma | TMA | NR | NR | NA | 80 | Nuclear & cytoplasmic | ✓ | ✓ |
| Teixeira | 2015 | Oral cancer | NR | 25 aged < 62, 29 aged ≥ 62 |
Males & females | NA | 54 | Nuclear & cytoplasmic | ✓ | ✓ |
| Thoma | 2009 | Renal | TMA | NR | NR | NA | > 200 | Nuclear | ✓ | X |
| Uemura | 2009 | Esophageal | TMA | 32 aged < 60, 28 aged ≥ 60 |
Males & females | 60 | 60 | Nuclear & cytoplasmic | ✓ | X |
| Wang | 2009 | Gastric | TMA | NR | Males & females | 102 | 102 | Nuclear & cytoplasmic | ✓ | ✓ |
| Yu | 2010 | Osteosarcoma | NR | 12–54 (25.2) | Males & females | 20 | 48 | Nuclear & cytoplasmic | ✓ | ✓ |
| Zhang | 2008 | Hepatocellular | TMA | 184 <median age, 216> median age | Males & females | NR | 400 | Nuclear | X | ✓ |
| Zhao | 2014 | Endometrial | NR | NR (50.8) | Females | 30 | 63 | Nuclear & cytoplasmic | ✓ | X |
NA = not applicable, NR = not reported, TMA = tissue microarray, UC = Ulcerative Colitis.